US drugmaker AbbVie and China’s FutureGen Biopharmaceutical have announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treat 13 June 2024
The Center for Drug Evaluations of the National Medical Products Administration (NMPA) in China has accepted the biologics license application (BLA) for zanidat 11 June 2024
Globally, the devastating and widespread impact of neurological disorders like Alzheimer's disease, epilepsy, Parkinson’s disease and depression is only getting 30 May 2024
Bio-Thera Solutions has partnered with STADA Arzneimittel for the commercialization of BAT2506, a biosimilar candidate to Simponi (golimumab). 30 May 2024
USA-based Nippon Shinyaku (TYO: 4516) subsidiary NS Pharma has published a disappointing initial analysis from an important trial of Viltepso (viltolarsen). 28 May 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.